Personalised medicine approach may hold benefit for late-stage cancer patients
This article was originally published in Scrip
Executive Summary
A personalised medicine approach appeared to benefit some late-stage cancer patients whose tumours were considered refractory to standard therapy in a pilot study highlighted at a special plenary session at the American Association for Cancer Research (AACR) meeting in Denver.